Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTL001 in advanced solid tumors
NCT06410092Phase 1Recruiting
- Sponsor
- Sound Biopharmaceuticals
- Start
- Jun 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of FTL001 in solid tumor (advanced stage) (2 arms), sponsored by Sound Biopharmaceuticals. Primary endpoint: Number of participants with dose-limiting toxicities. Started Jun 2023; status: recruiting.
02
Drugs
FTL001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06410092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06410092.